Literature DB >> 27474881

Extracellular vesicles carry microRNA-195 to intrahepatic cholangiocarcinoma and improve survival in a rat model.

Ling Li1, Klaus Piontek1, Masaharu Ishida1,2, Michel Fausther3, Jonathan A Dranoff3, Rongdang Fu1, Esteban Mezey1, Stephen J Gould4, Francis K Fordjour4, Stephen J Meltzer1, Alphonse E Sirica5, Florin M Selaru1,6,7.   

Abstract

The cancer microenvironment plays a central role in cancer development, growth, and homeostasis. This paradigm suggests that cancer fibroblasts support cancers, probably in response to stimuli received from the cancer cells. We aimed at investigating whether extracellular vesicles (EVs) can shuttle microRNA (miR) species between cancer-associated fibroblasts (CAFs) and cancer cells. To this end, we extracted EVs according to published protocols. EVs were studied for their miR content by quantitative reverse-transcription polymerase chain reaction. EVs were transfected with select miR species and utilized in vitro as well as in vivo in a rat model of cholangiocarcinoma (CCA). We found that miR-195 is down-regulated in CCA cells, as well as in adjoining fibroblasts. Furthermore, we report that EVs shuttle miR-195 from fibroblasts to cancer cells. Last, we show that fibroblast-derived EVs, loaded with miR-195, can be administered in a rat model of CCA, concentrate within the tumor, decrease the size of cancers, and improve survival of treated rats.
CONCLUSION: EVs play a salient role in trafficking miR species between cancer cells and CAFs in human CCA. Understanding of these mechanisms may allow devising of novel therapeutics. (Hepatology 2017;65:501-514).
© 2016 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27474881      PMCID: PMC5258762          DOI: 10.1002/hep.28735

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  44 in total

Review 1.  Role of cancer-associated fibroblasts in breast cancer development and prognosis.

Authors:  Abdelilah Aboussekhra
Journal:  Int J Dev Biol       Date:  2011       Impact factor: 2.203

Review 2.  The role of cancer-associated myofibroblasts in intrahepatic cholangiocarcinoma.

Authors:  Alphonse E Sirica
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-11-29       Impact factor: 46.802

3.  Establishment of a new extrahepatic bile duct carcinoma cell line, TFK-1.

Authors:  S Saijyo; T Kudo; M Suzuki; Y Katayose; M Shinoda; T Muto; K Fukuhara; T Suzuki; S Matsuno
Journal:  Tohoku J Exp Med       Date:  1995-09       Impact factor: 1.848

4.  A new human cholangiocellular carcinoma cell line (HuCC-T1) producing carbohydrate antigen 19/9 in serum-free medium.

Authors:  M Miyagiwa; T Ichida; T Tokiwa; J Sato; H Sasaki
Journal:  In Vitro Cell Dev Biol       Date:  1989-06

5.  BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progression.

Authors:  Aldo M Roccaro; Antonio Sacco; Patricia Maiso; Abdel Kareem Azab; Yu-Tzu Tai; Michaela Reagan; Feda Azab; Ludmila M Flores; Federico Campigotto; Edie Weller; Kenneth C Anderson; David T Scadden; Irene M Ghobrial
Journal:  J Clin Invest       Date:  2013-04       Impact factor: 14.808

6.  MicroRNA-195 suppresses tumorigenicity and regulates G1/S transition of human hepatocellular carcinoma cells.

Authors:  Teng Xu; Ying Zhu; Yujuan Xiong; Yi-Yuan Ge; Jing-Ping Yun; Shi-Mei Zhuang
Journal:  Hepatology       Date:  2009-07       Impact factor: 17.425

Review 7.  Classification, diagnosis, and management of cholangiocarcinoma.

Authors:  Nataliya Razumilava; Gregory J Gores
Journal:  Clin Gastroenterol Hepatol       Date:  2012-09-13       Impact factor: 11.382

Review 8.  Intrahepatic cholangiocarcinoma progression: prognostic factors and basic mechanisms.

Authors:  Alphonse E Sirica; Catherine I Dumur; Deanna J W Campbell; Jorge A Almenara; Olorunseun O Ogunwobi; Jennifer L Dewitt
Journal:  Clin Gastroenterol Hepatol       Date:  2009-11       Impact factor: 11.382

9.  Human bile contains microRNA-laden extracellular vesicles that can be used for cholangiocarcinoma diagnosis.

Authors:  Ling Li; David Masica; Masaharu Ishida; Ciprian Tomuleasa; Sho Umegaki; Anthony N Kalloo; Christos Georgiades; Vikesh K Singh; Mouen Khashab; Stuart Amateau; Zhiping Li; Patrick Okolo; Anne-Marie Lennon; Payal Saxena; Jean-Francois Geschwind; Todd Schlachter; Kelvin Hong; Timothy M Pawlik; Marcia Canto; Joanna Law; Reem Sharaiha; Clifford R Weiss; Paul Thuluvath; Michael Goggins; Eun Ji Shin; Haoran Peng; Vivek Kumbhari; Susan Hutfless; Liya Zhou; Esteban Mezey; Stephen J Meltzer; Rachel Karchin; Florin M Selaru
Journal:  Hepatology       Date:  2014-07-25       Impact factor: 17.425

10.  Hepatic stellate cells may relate to progression of intrahepatic cholangiocarcinoma.

Authors:  Hirohisa Okabe; Toru Beppu; Hiromitsu Hayashi; Kei Horino; Toshiro Masuda; Hiroyuki Komori; Shinji Ishikawa; Masayuki Watanabe; Hiroshi Takamori; Ken-ichi Iyama; Hideo Baba
Journal:  Ann Surg Oncol       Date:  2009-06-23       Impact factor: 5.344

View more
  47 in total

Review 1.  Cholangiocarcinoma: novel therapeutic targets.

Authors:  Keisaku Sato; Shannon Glaser; Domenico Alvaro; Fanyin Meng; Heather Francis; Gianfranco Alpini
Journal:  Expert Opin Ther Targets       Date:  2020-02-26       Impact factor: 6.902

2.  Extracellular vesicles as therapeutic carriers of microRNAs for cholangiocarcinoma.

Authors:  Sergio A Gradilone
Journal:  Hepatology       Date:  2016-12-24       Impact factor: 17.425

Review 3.  Emerging Technologies for the Diagnosis of Perihilar Cholangiocarcinoma.

Authors:  Sumera Rizvi; John Eaton; Ju Dong Yang; Vinay Chandrasekhara; Gregory J Gores
Journal:  Semin Liver Dis       Date:  2018-06-05       Impact factor: 6.115

4.  Exosome miR-335 as a novel therapeutic strategy in hepatocellular carcinoma.

Authors:  Fang Wang; Ling Li; Klaus Piontek; Masazumi Sakaguchi; Florin M Selaru
Journal:  Hepatology       Date:  2018-01-29       Impact factor: 17.425

5.  Hepatic stellate cells promote intrahepatic cholangiocarcinoma progression via NR4A2/osteopontin/Wnt signaling axis.

Authors:  Chu-Yu Jing; Yi-Peng Fu; Cheng Zhou; Mei-Xia Zhang; Yong Yi; Jin-Long Huang; Wei Gan; Juan Zhang; Su-Su Zheng; Bo-Heng Zhang; Shuang-Jian Qiu
Journal:  Oncogene       Date:  2021-03-19       Impact factor: 9.867

Review 6.  Targeting the tumor microenvironment in cholangiocarcinoma: implications for therapy.

Authors:  Juan Wang; Sumera Ilyas
Journal:  Expert Opin Investig Drugs       Date:  2020-12-28       Impact factor: 6.206

Review 7.  The Emerging Role of Immunotherapy in Intrahepatic Cholangiocarcinoma.

Authors:  Oraianthi Fiste; Ioannis Ntanasis-Stathopoulos; Maria Gavriatopoulou; Michalis Liontos; Konstantinos Koutsoukos; Meletios Athanasios Dimopoulos; Flora Zagouri
Journal:  Vaccines (Basel)       Date:  2021-04-22

Review 8.  The therapeutic potential of exosomes derived from different cell sources in liver diseases.

Authors:  Yun Pan; Wei-Feng Tan; Mu-Qing Yang; Ji-Yu Li; David A Geller
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2022-02-02       Impact factor: 4.052

Review 9.  Strategic design of extracellular vesicle drug delivery systems.

Authors:  James P K Armstrong; Molly M Stevens
Journal:  Adv Drug Deliv Rev       Date:  2018-06-28       Impact factor: 15.470

10.  Small extracellular vesicles containing miR-30a-3p attenuate the migration and invasion of hepatocellular carcinoma by targeting SNAP23 gene.

Authors:  Chengdong Liu; Xiaohan Zhou; Qian Long; Hanyi Zeng; Qingcan Sun; Yuting Chen; Dehua Wu; Li Liu
Journal:  Oncogene       Date:  2020-10-27       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.